(Q37893841)

24 August 2017

1 reference

title

The molecular pathogenesis of primary mediastinal large B-cell lymphoma (English)

1 reference

24 August 2017

0 references

2

Randy D Gascoyne

1 reference

24 August 2017

Christian Steidl

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

23 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

118

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

2659-2669

1 reference

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

24 August 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

5 December 2024

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases

5 December 2024

5

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)

5 December 2024

6

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The biology of Hodgkin's lymphoma

5 December 2024

7

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

5 December 2024

8

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

5 December 2024

9

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

5 December 2024

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

5 December 2024

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

5 December 2024

12

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

5 December 2024

13

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Primary mediastinal B-cell lymphoma.

5 December 2024

14

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children

5 December 2024

15

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

5 December 2024

16

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

5 December 2024

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

CNS involvement in primary mediastinal large B-cell lymphoma

5 December 2024

18

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience

5 December 2024

19

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients

5 December 2024

21

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma

5 December 2024

23

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma

5 December 2024

24

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

5 December 2024

25

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins

5 December 2024

27

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma

5 December 2024

28

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Expression of bcl-6 and CD10 in Primary Mediastinal Large B-Cell Lymphoma

5 December 2024

29

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

5 December 2024

32

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens

5 December 2024

33

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

CD30 expression is common in mediastinal large B-cell lymphoma

5 December 2024

34

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma

5 December 2024

36

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma

5 December 2024

39

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mediastinal (thymic) large B-cell lymphoma: where do we stand?

5 December 2024

40

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

5 December 2024

41

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc

5 December 2024

42

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Gains ofREL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein

5 December 2024

45

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).

5 December 2024

46

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction

5 December 2024

47

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation

5 December 2024

48

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling

5 December 2024

49

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Frequent occurrence of deletions in primary mediastinal B-cell lymphoma

5 December 2024

50

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

5 December 2024

51

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

5 December 2024

52

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma

5 December 2024

53

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Frequent inactivation of A20 in B-cell lymphomas

5 December 2024

54

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.

5 December 2024

55

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma

5 December 2024

56

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

STATs in cancer inflammation and immunity: a leading role for STAT3

5 December 2024

57

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets

5 December 2024

58

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236.

5 December 2024

59

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

5 December 2024

60

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Cooperative epigenetic modulation by cancer amplicon genes

5 December 2024

61

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation.

5 December 2024

62

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma

5 December 2024

63

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

5 December 2024

64

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6

5 December 2024

65

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.

5 December 2024

66

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

5 December 2024

67

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

5 December 2024

68

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

STAT6 in PMBL: pathogenic or passenger?

5 December 2024

69

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

5 December 2024

70

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

5 December 2024

71

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3

5 December 2024

72

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

5 December 2024

73

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

5 December 2024

74

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

5 December 2024

75

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.

5 December 2024

76

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol

5 December 2024

78

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

5 December 2024

79

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system

5 December 2024

80

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma

5 December 2024

81

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression

5 December 2024

83

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The bare lymphocyte syndrome and the regulation of MHC expression

5 December 2024

84

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants

5 December 2024

87

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

5 December 2024

88

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility

5 December 2024

90

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Isolation of a B-cell-specific promoter for the human class II transactivator

5 December 2024

91

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

PD-1 and its ligands in tolerance and immunity

5 December 2024

92

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma

5 December 2024

93

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma

5 December 2024

94

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

5 December 2024

95

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

5 December 2024

96

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma

5 December 2024

97

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

5 December 2024

98

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

5 December 2024

99

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2011-05-326538

5 December 2024

Identifiers

1 reference

24 August 2017

1 reference